(Q44261957)

English

A six-month, open-label study assessing a new formulation of leuprolide 7.5 mg for suppression of testosterone in patients with prostate cancer

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

1 December 2017

A six-month, open-label study assessing a new formulation of leuprolide 7.5 mg for suppression of testosterone in patients with prostate cancer (English)

1 reference

Europe PubMed Central

PubMed publication ID

1 December 2017

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

author name string

Ramon Perez-Marreno

1

1 reference

Europe PubMed Central

PubMed publication ID

1 December 2017

Franklin M Chu

2

1 reference

Europe PubMed Central

PubMed publication ID

1 December 2017

Donald Gleason

3

1 reference

Europe PubMed Central

PubMed publication ID

1 December 2017

Edward Loizides

4

1 reference

Europe PubMed Central

PubMed publication ID

1 December 2017

Barton Wachs

5

1 reference

Europe PubMed Central

PubMed publication ID

1 December 2017

Robert C Tyler

6

1 reference

Europe PubMed Central

PubMed publication ID

1 December 2017

publication date

1 November 2002

1 reference

Europe PubMed Central

PubMed publication ID

1 December 2017

Clinical Therapeutics

1 reference

Europe PubMed Central

PubMed publication ID

1 December 2017

24

1 reference

Europe PubMed Central

PubMed publication ID

1 December 2017

11

1 reference

Europe PubMed Central

PubMed publication ID

1 December 2017

1902-1914

1 reference

Europe PubMed Central

PubMed publication ID

1 December 2017

Cancer statistics, 1999.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2802%2980087-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Leuprolide acetate 22.5 mg 12-week depot formulation in the treatment of patients with advanced prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2802%2980087-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Clinical study of leuprolide depot formulation in the treatment of advanced prostate cancer. The Leuprolide Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2802%2980087-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Comparison of LH-RH analogue 1-month depot and 3-month depot by their hormone levels and pharmacokinetic profile in patients with advanced prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2802%2980087-X

7 January 2021

based on heuristic

inferred from DOI database lookup

An evaluation of pharmacokinetics and pharmacodynamics of leuprorelin acetate 3M-depot in patients with advanced and metastatic carcinoma of the prostate

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2802%2980087-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Sustained suppression of pituitary-gonadal axis with an injectable, in situ forming implant of leuprolide acetate

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2802%2980087-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Leuprorelin. A review of its pharmacology and therapeutic use in prostatic cancer, endometriosis and other sex hormone-related disorders

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2802%2980087-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Development of GnRH antagonists for prostate cancer: new approaches to treatment

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2802%2980087-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Sudden death due to disease flare with luteinizing hormone-releasing hormone agonist therapy for carcinoma of the prostate.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2802%2980087-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Efficacy and safety of leuprorelin acetate depot for prostate cancer. The German Leuprorelin Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2802%2980087-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1016/S0149-2918(02)80087-X

1 reference

Europe PubMed Central

PubMed publication ID

1 December 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

1 December 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q44261957&oldid=2108974663"